V2 vasopressin receptor abundance. by Sophie Constantin Lütken (689916)

Subjects:

Changes in neural activity were decreased in animals pre-exposed to 5-HT and <i>mod-1</i> mutants when the worms switched their locomotive direction. by Haruka Mori (8082215)

“…<p>(A–F) the neural activity of the RID changes during the transition periods from backward to forward locomotion (A–C) and from forward to backward locomotion (D–F) in the mock (A: p = 1.5 × 10⁻⁵; D: p = 5.5 × 10⁻¹³), 5-HT exposed (B: p = 0.092; E: p = 0.79), and <i>mod-1</i> mutant (C: p = 0.081; F: p = 0.93) groups. …”

<i>Ext1</i> mutant lungs exhibit a decrease in SHH-FGF10 signaling. by Hua He (120374)

“…<p>(A) qPCR analysis of key components of FGF signaling pathway in lungs from E14.5. …”

The long-term impact of sustained exposure-reducing interventions (represented by a decrease in density of female anophelines). by Azra C. Ghani (160248)

HemaMax administration decreased leukopenia (a) and thrombocytopenia (b) at nadir in irradiated, unsupported rhesus monkeys. by Lena A. Basile (331369)

Intrathecal injection of mycolactone triggers a decrease of pro-inflammatory cytokines in spinal cord of Sham rats. by Caroline Isaac (4600654)

Site-specific evolutionary rates increase with distance to a catalytic residue in 80% of residues. by Benjamin R. Jack (2637040)

Cell death and reactive gliosis induced by severe IVH showed a decrease after dexamethasone treatment. by Jang Hoon Lee (5897096)

Effect of SNX5 S226 phosphorylation on macropinocytosis. by Nao Itai (5954666)

Subjects:

Diagnostic performance of blood parameters to discriminate abnormal from normal MAD activity (A) and decreased from absent MAD activity (B). by Fabrice Rannou (775170)

“…(B) Classifiers for the differentiation of Absent (n = 5) from Decreased (n = 6) MAD activity. 50% PMP: 50% from predicted maximal power (see <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0132972#sec006" target="_blank">Methods</a>), R: Recovery from exercise, Se: Sensibility, Sp: Specificity, Acc: Accuracy, PPV: Positive predictive value, NPV: Negative predictive value, LR+: Positive likelihood ratio, LR-: Negative likelihood ratio, DOR: Diagnostic odds ratio, NC: Not calculable.…”

MRV decreases the post-therapy viral load set point. by Iart Luca Shytaj (157809)

Automated wound healing assay showing decreased motility of IL-4 treated HCAEC. by Tom Skaria (2733439)

Transforming growth factor (TGF)-β1 induced a robust decrease in S-phase in non-cancer cell strains by Kimberly A Brown (26546)

“…</p> Human primary cells and human and mouse established cell lines were treated with (TGF-β1) or without (control) 5 ng/ml TGF-β1 for 48 hours. The cells were then harvested and incubated with propidium iodide, and DNA content was determined using a FACS Caliber (Becton-Dickinson). …”

Luciferase expression in mice after intravenous injection rH17d’-Ad5 vectors as revealed by live BLI. by Christopher M. Gentile (6640331)

List of Included studies. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

The search strategy in three databases. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

NIH score. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

List of excluded studies. by Zahra Tajik (20752452)

“…There is no significant difference one month after NSPT in diabetic patients (SMD: -5.83, 95%CI: -15.5, 3.83, p = 0.237, I-square, 97.4%, random effects model, n = 2), but three (SMD: -2.44, 95%CI: -3.37, -1.15, p = 0.001, I-square, 75.9%, random effects model, n = 3) and six months (SMD: -2.41, 95%CI: -3.81, -1.01, p = 0.001, I-square, 78.7%, random effects model, n = 2) after the treatment, a significant decrease is observed in the mean GCF visfatin level. …”

Reduction of IL-8 is associated with a relevant decrease of GBA2 expression in CF bronchial cells. by Nicoletta Loberto (2224150)

Nilotinib decreases HEI-193 cell viability in a time-, dose-, and growth condition- dependent manner. by Nesrin Sabha (127278)

“…(B) HEI-193 grown in PDGF media were treated with 0, 3, 5, 10 or 20 µM nilotinib up to 5 days. Trypan blue viability assay shows decreased number of viable cells at 5 days in 3 µM nilotinib, compared to vehicle shown, mean and SD of six technical replicates. …”